Back to top
more

ARAVIVE (ARAV)

(Delayed Data from NSDQ)

$0.04 USD

0.04
NA

0.00 (0.00%)

Updated Jan 26, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks News

Aravive (ARAV) Upgraded to Buy: Here's Why

Aravive (ARAV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Is Aravive (ARAV) Outperforming Other Medical Stocks This Year?

Here is how Aravive (ARAV) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.

Aravive (ARAV) Reports Q3 Loss, Tops Revenue Estimates

Aravive (ARAV) delivered earnings and revenue surprises of -26.19% and 2.20%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Aravive (ARAV) Reports Q1 Loss, Lags Revenue Estimates

Aravive (ARAV) delivered earnings and revenue surprises of 2.22% and -54.69%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Aravive (ARAV) Stock Moves -1.47%: What You Should Know

In the latest trading session, Aravive (ARAV) closed at $14.11, marking a -1.47% move from the previous day.

Aravive (ARAV) Dips More Than Broader Markets: What You Should Know

Aravive (ARAV) closed at $13.55 in the latest trading session, marking a -0.88% move from the prior day.

Aravive (ARAV) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Aravive (ARAV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aravive (ARAV) Flat As Market Gains: What You Should Know

In the latest trading session, Aravive (ARAV) closed at $11.96, marking no change from the previous day.

Aravive (ARAV) Gains But Lags Market: What You Should Know

Aravive (ARAV) closed at $13.82 in the latest trading session, marking a +0.88% move from the prior day.

Is ARAVIVE, INC (ARAV) Outperforming Other Medical Stocks This Year?

Is (ARAV) Outperforming Other Medical Stocks This Year?

Aravive's Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Aravive.

bluebird bio (BLUE) Catches Eye: Stock Jumps 6%

bluebird bio (BLUE) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Top Ranked Momentum Stocks to Buy for April 20th

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 20th

Aravive (ARAV) in Focus: Stock Moves 8% Higher

Aravive (ARAV) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Outlook Therapeutics (OTLK) Catches Eye: Stock Jumps 7.6%

Outlook Therapeutics (OTLK) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Myovant Sciences (MYOV) Jumps: Stock Rises 8.3%

Myovant Sciences (MYOV) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Aravive (ARAV): Strong Industry, Solid Earnings Estimate Revisions

Aravive (ARAV) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Yash Killa headshot

Provention Bio (PRVB) Soars: Stock Adds 6.4% in Session

Provention Bio (PRVB) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Implied Volatility Surging for Aravive (ARAV) Stock Options

Investors need to pay close attention to Aravive (ARAV) stock based on the movements in the options market lately.

Aravive (ARAV) Reports Q2 Loss, Tops Revenue Estimates

Aravive (ARAV) delivered earnings and revenue surprises of 51.79% and 205.40%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?